During the past decade, Boehringer Ingelheim conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Boehringer Ingelheim" are "Diabetes Mellitus, Type 2" (3 trials), "Atrial Fibrillation" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "Boehringer Ingelheim" in a lesser frequency.

Most popular intervention types in "Boehringer Ingelheim" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Empagliflozin" (2 trials), "DPP-4i" (1 trials), "GLP-1-RA" (1 trials), "Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Boehringer Ingelheim" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Boehringer Ingelheim". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Boehringer Ingelheim, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Boehringer Ingelheim, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".